Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ANNX vs ENTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

ENTA Overall Winner 6-Pillar Tally: ANNX 2 – 3 ENTA (1 Tie) Matrix Metrics: ANNX 5 – 5 ENTA

As of Nov 16, 2026, Enanta Pharmaceuticals, Inc (ENTA) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ANNX carries a Unified Composite Score of 44.6/100 (HOLD) at $3.57 (N/M Forward P/E, 0.0% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.67 (44.0x Forward P/E, -90.0% operating margin).

  • Growth vs. Quality Trade-Off: ENTA earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. ANNX 44.6/100 HOLD) and 0.88β · 58% Vol risk profile, whereas ANNX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.9); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANNX vs ENTA
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.57
-8.93% 1D
Market Cap $747.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.68β · 62% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 42.0 Fund 54.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.3%), weak momentum, RSI 38
RSI-14: 37.9 · SMA20: $3.98 · SMA50: $4.00
ENTA NASDAQ Head-to-Head Winner
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.67
-2.91% 1D
Market Cap $320.1M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.88β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88

6-Pillar Scorecard Institutional Category Breakdown (ANNX 2 – 3 ENTA)

Columns: Metric · ANNX · ENTA
1. Valuation Multiples ENTA
Forward P/E N/M 44.0x
Trailing P/E N/M 44.0x
PEG Ratio N/M N/M
EV / Revenue N/M 5.2x
2. Growth & Scale ANNX
Revenue Growth (YoY) +0.0% -21.6%
Earnings Growth (YoY) +0.0% -66.2%
TTM Revenue (USD) N/A $65M
Market Cap $747.8M $320.1M
3. Profitability & Quality ANNX
Gross Margin N/A 100.0%
Operating Margin 0.0% -90.0%
Net Profit Margin 0.0% -96.9%
Return on Equity (ROE) -130.8% -70.1%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$190M -$37M
Cash Flow Margin N/A -56.6%
Net Cash / Leverage $29M Net Cash $22M Net Debt (0.55x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 569.3% (100th %ile) 78.7% (11th %ile)
Put/Call OI Skew 0.75x (Call-Skewed) 0.31x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANNX (5) vs ENTA (5)
Institutional Metric ANNX ENTA Criterion Row Edge
Market Capitalization
Scale
$747.8M $320.1M Larger Scale ANNX
Trailing P/E Ratio
Valuation
N/M 44.0x Lower Multiple ENTA
Forward P/E Ratio
Valuation
N/M 44.0x Lower Multiple ENTA
Revenue Growth (YoY)
Growth
+0.0% -21.6% Higher Growth ANNX
Operating Margin (TTM)
Profitability
0.0% -90.0% Higher Margin ANNX
Net Profit Margin
Profitability
0.0% -96.9% Higher Margin ANNX
Return on Equity (ROE)
Capital Efficiency
-130.8% -70.1% Higher ROE ENTA
52-Week Range Position
Momentum
22% ($3–$7) 9% ($10–$17) Stronger Trend ANNX
Beta / 30D Volatility
Risk Regime
1.68β · 62% Vol 0.88β · 58% Vol Lower Realized Risk ENTA
Unified Institutional Score
Composite Signal
44.6 / 100 (HOLD) 46.2 / 100 (HOLD) Higher Composite ENTA
Trailing 12M Revenue (USD)
Operating Scale
N/A $65M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$190M ($29M Net Cash) -$37M ($22M Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANNX +8.56 pp
ANNX: +4.69% · ENTA: -3.87%
3M Horizon ENTA +12.62 pp
ANNX: -32.39% · ENTA: -19.77%
6M Horizon ENTA +7.35 pp
ANNX: -28.02% · ENTA: -20.67%
1Y Horizon ANNX +42.17 pp
ANNX: +33.21% · ENTA: -8.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs ENTA. Trailing 12-month operating profitability (ANNX 0.0% vs ENTA -90.0%) and valuation multiples (ANNX N/M vs ENTA 44.0x Forward P/E) are benchmarked directly in Pillar 4 below.

ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M
ENTA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$65M
Gross Margin100.0%
Op. Margin-90.0%
ROE / Fwd P/E-70.1% · 44.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANNX BREAKDOWN
87d in phase · OBV DISTRIBUTION
Current IV 569.3%
IV Percentile 100th %ile
Put/Call OI Skew 0.75x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $320.1M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANNX vs ENTA Key Questions & Quantitative Answers

As of Nov 16, 2026, Enanta Pharmaceuticals, Inc (ENTA) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ANNX carries a Unified Composite Score of 44.6/100 (HOLD) at $3.57 (N/M Forward P/E, 0.0% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.67 (44.0x Forward P/E, -90.0% operating margin). Growth vs. Quality Trade-Off: ENTA earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. ANNX 44.6/100 HOLD) and 0.88β · 58% Vol risk profile, whereas ANNX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.9); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANNX leads the Growth & Scale pillar: ANNX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENTA at -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin). On trailing 12-month operating scale, ANNX generates N/A in USD-normalized revenue versus $65M for ENTA. In operating R&D and SG&A reinvestment, ANNX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTA.

ENTA screens cheaper on headline valuation multiples. ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.2x EV/Revenue (-56.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANNX (-130.8% ROE) versus ENTA (-70.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.75x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 62% Vol realized risk). By comparison, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.88β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.